Non-coding RNAs in drug resistance of head and neck cancers: A review - 30/05/20
pages | 13 |
Iconographies | 5 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Highlights |
• | miRNAs mainly affect HNC drug resistance by influencing the expression of their target mRNAs and by regulating apoptosis pathways, EMT, and CSCs. |
• | lncRNAs are widely involved in HNC resistance to cisplatin, paclitaxel, 5-fluorouracil, and doxorubicin. |
• | circRNAs may have an important regulatory role in the mechanism of tumor resistance in HNCs. |
• | Non-coding RNAs have crucial roles in HNC drug resistance and provide novel insights into HNC therapeutic resistance. |
Abstract |
Head and neck cancer (HNC), which includes epithelial malignancies of the upper aerodigestive tract (oral cavity, oropharynx, pharynx, hypopharynx, larynx, and thyroid), are slowly but consistently increasing, while the overall survival rate remains unsatisfactory. Because of the multifunctional anatomical intricacies of the head and neck, disease progression and therapy-related side effects often severely affect the patient’s appearance and self-image, as well as their ability to breathe, speak, and swallow. Patients with HNC require a multidisciplinary approach involving surgery, radiation therapy, and chemotherapeutics. Chemotherapy is an important part of the comprehensive treatment of tumors, especially advanced HNC, but drug resistance is the main cause of poor clinical efficacy. The most important determinant of this phenomenon is still largely unknown. Recent studies have shown that non-coding RNAs have a crucial role in HNC drug resistance. In addition, they can serve as biomarkers in the diagnosis, treatment, and prognosis of HNCs. In this review, we summarize the relationship between non-coding RNAs and drug resistance of HNC, and discuss their potential clinical application in overcoming HNC chemoresistance.
Le texte complet de cet article est disponible en PDF.Keywords : Head and neck cancer, Non-coding RNA, MicroRNA, Long non-coding RNA, Circular RNA, Drug resistance, Chemoresistance
Plan
Vol 127
Article 110231- juillet 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?